<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04759820</url>
  </required_header>
  <id_info>
    <org_study_id>CRC-SH02</org_study_id>
    <nct_id>NCT04759820</nct_id>
  </id_info>
  <brief_title>Carbon Nanoparticles vs Indocyanine Green</brief_title>
  <official_title>A Multicentre Randomized Controlled Clinical Study of the Efficacy of Carbon Nanoparticles Versus Indocyanine Green in Surgical Treatment of Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LI XIN-XIANG</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Both nano carbon and ICG as lymph node tracers in colorectal cancer have their own value,&#xD;
      this study was to contrast two tracers in colorectal cancer surgeries, so as to find out the&#xD;
      best lymphnode tracer in colorectal cancer, in order to further improve postoperative lymph&#xD;
      node inspection, precise postoperative adjuvant therapy and improve the patients' long-term&#xD;
      survival.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of lymph nodes detected</measure>
    <time_frame>1 week after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of positive lymph nodes detected at different T stages</measure>
    <time_frame>1 week after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>the ratio of positive lymph nodes</measure>
    <time_frame>1 week after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>patients' Disease-Free Survival(DFS)</measure>
    <time_frame>1 year after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">298</enrollment>
  <condition>Number of Lymph Node Retrieved</condition>
  <arm_group>
    <arm_group_label>Nano carbon group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of carbon nanoparticle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Indocyanine green group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection of indocyanine green</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>injecting Carbon Nanoparticles Suspension</intervention_name>
    <description>injecting Carbon Nanoparticles Suspension for lymph node detection</description>
    <arm_group_label>Nano carbon group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Injecting indocyanine green</intervention_name>
    <description>Injecting indocyanine green for lymph node detection</description>
    <arm_group_label>Indocyanine green group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Colorectal cancer was confirmed by preoperative fibrocolonoscopy and pathological&#xD;
             examination;&#xD;
&#xD;
          2. The operative requirements of the patients included in the study: laparoscopic radical&#xD;
             surgery of colon/rectal cancer, indocyanine green group should be used fluorescent&#xD;
             laparoscopic (Pinpoint) surgery;&#xD;
&#xD;
          3. The lower edge of the lesion is located more than 10cm from the anus;&#xD;
&#xD;
          4. Age 18 ~ 70;&#xD;
&#xD;
          5. The results of laboratory examination before enrollment met the following surgical&#xD;
             conditions: neutrophils (ANC) ≥1.5×109/L, platelets (PLT) ≥ 100×109/L, total bilirubin&#xD;
             (TBI) ≤1.5× upper limit of normal (2mg/ dL), alanine aminotransferase (ALT), ascarate&#xD;
             aminotransferase (AST) ≤2× upper limit of normal;The coagulation parameters were in&#xD;
             the normal range.&#xD;
&#xD;
          6. Patients had no psychological, family, social, or geographical constraints that&#xD;
             affected protocol compliance and follow-up time&#xD;
&#xD;
          7. Patient signs informed consent;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Under 18 years old or above 70 years old;&#xD;
&#xD;
          2. Other types of colorectal cancer (adenosquamous cell carcinoma, squamous cell&#xD;
             carcinoma, neuroendocrine tumor, clear cell carcinoma, spindle cell carcinoma,&#xD;
             undifferentiated carcinoma)&#xD;
&#xD;
          3. Rectum cancer less than 10cm from the anus;&#xD;
&#xD;
          4. Previous abdominal surgery;&#xD;
&#xD;
          5. Neoadjuvant therapy was received preoperatively, including radiotherapy and&#xD;
             chemotherapy;&#xD;
&#xD;
          6. Due to various reasons, preoperative colonoscopic injection of carbon&#xD;
             nanoparticles/indocyanine green labeling was not possible;&#xD;
&#xD;
          7. Intraoperative radical surgery cannot be performed due to various reasons;&#xD;
&#xD;
          8. Acute abdomen: intestinal obstruction, intestinal wringing, peritonitis, etc.;&#xD;
&#xD;
          9. Combined with other site metastasis;&#xD;
&#xD;
         10. Have severe heart, lung, liver and kidney diseases and cannot tolerate surgery;&#xD;
&#xD;
         11. Active stage of liver disease or abnormal liver function, ALT, AST, TBIL more than&#xD;
             twice the upper limit of normal value;&#xD;
&#xD;
         12. Renal function impairment, Cr≥2 times the upper limit of normal or BUN≥2 times the&#xD;
             upper limit of normal;&#xD;
&#xD;
         13. The subjects' white blood cells are lower than the lower limit of normal value, or&#xD;
             their platelets are lower than the lower limit of normal value, or have other diseases&#xD;
             of the blood system;&#xD;
&#xD;
         14. People with mental illness or mental retardation who cannot describe their feelings&#xD;
             correctly;&#xD;
&#xD;
         15. Severe disorder of coagulation mechanism and bleeding tendency;&#xD;
&#xD;
         16. Have a history of serious uncontrolled medical disease or recent myocardial infarction&#xD;
             (within 3 months);Acute infection;&#xD;
&#xD;
         17. Patients with uncontrolled severe hypertension and severe diabetes after intervention&#xD;
             treatment;&#xD;
&#xD;
         18. Allergic to the test drug;&#xD;
&#xD;
         19. A history of alcohol, drug or substance abuse;&#xD;
&#xD;
         20. Participants who had participated in any drug trial within 3 months prior to&#xD;
             enrollment;&#xD;
&#xD;
         21. Other subjects considered by the researcher to be unsuitable for inclusion in this&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xinxiang Li, MD</last_name>
    <phone>86-21-64175590</phone>
    <email>lxx1149@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinxiang Li, MD</last_name>
      <phone>86-21-64175590</phone>
      <email>lxx1149@163.com</email>
    </contact>
    <investigator>
      <last_name>Renjie Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 7, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>LI XIN-XIANG</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

